# Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia

> **NCT04607252** · PHASE2,PHASE3 · TERMINATED · sponsor: **Fudan University** · enrollment: 12 (actual)

## Conditions studied

- Atypical Endometrial Hyperplasia

## Interventions

- **DRUG:** Metformin plus Megestrol acetate
- **DRUG:** Megestrol Acetate

## Key facts

- **NCT ID:** NCT04607252
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-11
- **Primary completion:** 2021-06-03
- **Final completion:** 2021-06-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Our clinical trial NCT03241888 showed LNG-IUS had a better treatment efficacy than Megestrol Acetate (MA) alone. The median CR time for MA group, LNG-IUS group and MA plus LNG-IUS group was 7.0±0.3 months, 4.4±1.0 months and 5.7±1.2 months.
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04607252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04607252, "Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04607252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*